Skip to main content

Advertisement

ADVERTISEMENT

Diffuse Large B-Cell Lymphoma News

News
08/30/2024
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a retrospective study, among patients with relapsed large B-cell lymphoma who achieve a complete remission, treatment with autologous hematopoietic cell transplantation is associated with improved clinical outcomes...
According to results from a...
08/30/2024
Oncology
News
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology

Advertisement

News
02/28/2024

Amber Denham

Amber Denham
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up data from the TRANSCEND NHL 001 trial, lisocabtagene maraleucel continues to demonstrate high response rates, durable remissions, and a manageable safety profile among patients with relapsed/refractory large...
According to 2-year follow-up...
02/28/2024
Oncology
News
02/21/2024
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
02/02/2024
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology

Advertisement

News
01/11/2024
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and lenalidomide demonstrated feasibility and moderate activity as frontline therapy for older patients with diffuse large B-cell lymphoma, according to a recent study.
The combination of rituximab and...
01/11/2024
Oncology
News
01/03/2024
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in assessing the controlling nutritional status (CONUT) score for older patients with DLBCL treated with R-CHOP-like regimens, according to a recent study.
Prognostic value was found in...
01/03/2024
Oncology
News
01/03/2024
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature was found to be useful in identifying diffuse large B-cell lymphoma subtypes vulnerable to BTK inhibitor therapies, according to a recent study.
A CD5 gene expression signature...
01/03/2024
Oncology

Advertisement

Conference Coverage
12/11/2023
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2 TAZ R-CHOP study demonstrate that R-CHOP plus tazemetostat is a feasible treatment option among older patients with newly diagnosed diffuse large B-cell lymphoma.
Efficacy results of the phase 2...
12/11/2023
Oncology

Advertisement